PTEN and prostate cancer: Although dual inhibition of p110α+p110β can efficiently block PI3K relief of feedback inhibition and achieve potent anti-tumor effect in some prostate cancers harboring loss of PTEN, we also identified that resistance to p110α+p110β inhibition can occur through IGF1R-mediated PI3K residual activity.